Chimeric antigen receptor T-cell (CAR-T) therapies reached NHS routine commissioning in 2018 for paediatric B-cell acute lymphoblastic leukaemia (tisagenlecleucel, NICE TA559) and diffuse large B-cell lymphoma (axicabtagene ciloleucel, TA567), and the indications have expanded steadily since. Today, a community pharmacist in a large city can reasonably expect to occasionally see a patient who has received CAR-T therapy. Numbers are low, but the medication profile is distinctive enough to be worth knowing.
What CAR-T does to the pharmacy record
CAR-T is an autologous cell therapy. T-cells are collected, engineered to express a receptor targeting a tumour antigen (most commonly CD19 or BCMA), and reinfused after lymphodepleting chemotherapy. Patients typically spend two to four weeks in a specialist unit for monitoring, principally for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Those complications are managed in hospital. It is the post-discharge phase where community pharmacy becomes relevant.
The typical discharge medication list
Prophylactic antivirals. Aciclovir (typically 400 mg twice daily or 200 mg three times daily, adjusted for renal function) is standard for at least six months post-infusion to suppress varicella zoster and herpes simplex reactivation. Adherence counselling is useful; suppressive aciclovir is a daily long-term commitment that looks small on paper but is clinically important.
Pneumocystis jirovecii pneumonia prophylaxis. Co-trimoxazole is first line, typically 480 mg once daily or 960 mg three times weekly. Duration is usually at least six months and often longer if the patient has persistent B-cell aplasia. Patients with sulfonamide allergy or cytopenias may be on dapsone, atovaquone or pentamidine instead — all specialist-initiated.
Antifungal prophylaxis. Some centres prescribe fluconazole, posaconazole or itraconazole during the deep neutropenia window. By the time a patient is in the community this has usually stopped, but check the discharge letter.
Immunoglobulin replacement. B-cell directed CAR-T therapies (CD19, BCMA) predictably cause hypogammaglobulinaemia. Many patients are on intravenous or subcutaneous immunoglobulin replacement (IVIG or SCIG). This is usually dispensed directly through homecare providers rather than community pharmacy, but community pharmacy may dispense small-volume ancillaries (needles, transfer sets for SCIG) or short courses of antibiotics for breakthrough infections. Homecare providers such as Sciensus, Lloyds Clinical Homecare and HealthNet Homecare operate outside the public jobs feeds tracked by PharmSee — a reminder that a meaningful slice of specialty pharmacy sits adjacent to, rather than inside, the community network.
Corticosteroids. Short tapers of dexamethasone may be carried home if a patient was managed for late-onset neurotoxicity. Steroid withdrawal counselling matters.
The vaccination picture
Lymphodepleting chemotherapy resets much of the adaptive immune system, and B-cell aplasia can persist for many months after treatment. Revaccination is delayed compared with a conventional haematopoietic transplant schedule, with live vaccines generally deferred until B-cell recovery and acceptable immunoglobulin levels are demonstrated. Community pharmacy vaccination teams should not vaccinate post-CAR-T patients without written confirmation from the specialist centre that the patient is cleared.
Red flags at the counter
| Signal | Why it matters |
|---|---|
| New fever, confusion, or new neurological symptom | Late neurotoxicity or infection — urgent referral |
| Missed aciclovir or co-trimoxazole doses over several days | Reactivation risk rises rapidly |
| Request for NSAIDs or over-the-counter anticoagulants | Thrombocytopenia may persist; check counts |
| New shingles-like rash | Breakthrough VZV — urgent specialist contact |
| Requests for travel vaccines | Live vaccines often contraindicated; refer |
What community pharmacy can usefully offer
CAR-T patients are, by definition, people who have been through intensive treatment and may find repeat medication reviews valuable. The New Medicine Service and Structured Medication Review pathways are appropriate where indicated, with the caveat that changes to prophylactic regimens are specialist-led. The most valuable community pharmacy intervention is often the simplest — confirming adherence to the prophylactic antimicrobials that prevent late-onset opportunistic infection.
The broader sector context is one of sustained workload: PharmSee's tracker recorded 1,651 live UK pharmacy vacancies on 14 April 2026, with NHS Jobs contributing 452. Specialty aftercare adds to, rather than replaces, routine counter demand.
Caveats
This article describes a typical pattern. Individual regimens vary by CAR-T product, by disease, by centre and by the patient's comorbidity profile. Always work from the discharge letter rather than inferring a regimen from the diagnosis alone. For product-specific information consult the relevant SmPC and NICE technology appraisal.
Sources
- NICE TA559, TA567 and subsequent CAR-T technology appraisals.
- NHS England Cancer Drugs Fund and specialised commissioning pathways.
- British Society for Haematology guidelines on CAR-T aftercare.
- PharmSee live jobs-board tracker, 14 April 2026.